Literature DB >> 35871446

Papillary thyroid cancer with Hashimoto's thyroiditis attenuates the tumour aggressiveness through the up-regulation of E-cadherin and TGF-β expression.

Su Jin Kim1, Seung-Eun Lee2, Young Il Kim2, Il Sung Nam-Goong2, Hyo Won Jung3, Eun Sook Kim4.   

Abstract

Human papillary thyroid cancer (PTC) is often associated with Hashimoto's thyroiditis (HT), and their coexistence improves the prognosis of PTC. Aim of the study. The objective of our study is to investigate the expression of cadherins and TGF-β which are regulators in the tumour aggressiveness with metastatic spread in PTC patients and its relationship with HT. The expression of E-cadherin and N-cadherin was measured in thyroid tissues of healthy volunteers and PTC patients with HT (PTC/HT) or without. The E-cadherin expression was also determined in thyroid cancer cells (TPC1, SNU373, SNU790, 8505C, CAL62, and FTC133). Cell migration was measured by wound healing assay. The expression of N-cadherin, ICAM1, and TGF-β was measured in thyroid tissues and plasma. The E-cadherin expression was significantly increased in PTC/HT patients compared with PTC alone. Meanwhile, the N-cadherin expression was significantly decreased in PTC/HT patients. The E-cadherin expression was only observed in FTC cells, and the overexpression of E-cadherin inhibited cancer cell migration. The TGF-β expression was significantly increased in PTC/HT patients, and the plasma levels were higher in PTC/HT patients than in PTC alone. The expression of N-cadherin and ICAM-1 was significantly decreased in PTC/HT patients. Our results indicate that the expression of E-cadherin and TGF-β was higher in PTC/HT patients than in PTC alone. This suggests that the presence of PTC with HT may attenuate the tumour aggressiveness and metastasis through the up-regulation of E-cadherin and TGF-β expression.
© 2022. The Author(s).

Entities:  

Keywords:  E-cadherin; Hashimoto’s thyroiditis; Papillary thyroid cancer; Transforming growth factor beta

Year:  2022        PMID: 35871446     DOI: 10.1007/s10238-022-00857-6

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   5.057


  2 in total

1.  Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues.

Authors:  Sarah H Hayes; Gail M Seigel
Journal:  Int J Clin Exp Pathol       Date:  2009-06-10

2.  Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area.

Authors:  Jin Young Kwak; Eun-Kyung Kim; Jong-Kee Kim; Jeong-Hyun Han; Soon Won Hong; Tae Sung Park; Jong Rak Choi
Journal:  Head Neck       Date:  2010-04       Impact factor: 3.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.